Pharma · Private company
Astellas Pharma Inc
Track this companyFree. Adds Astellas Pharma Inc to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- ASP5834Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- FluorouracilPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- IrinotecanPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- LeucovorinPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- panitumumabPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- SetidegrasibPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract CancersPHASE2 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07723534 · fetched Nov 12, 2026
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal AdenocarcinomasPHASE2 · RECRUITING · started Jul 20, 2026ClinicalTrials.gov NCT07290985 · fetched Nov 12, 2026
- Study of EV for Recurrent Endometrial CarcinomaPHASE2 · RECRUITING · started Jul 10, 2026ClinicalTrials.gov NCT07139977 · fetched Nov 12, 2026
- Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerPHASE1_PHASE2 · RECRUITING · started Mar 11, 2026ClinicalTrials.gov NCT07421700 · fetched Nov 12, 2026
- Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation TherapyPHASE2 · RECRUITING · started Jan 14, 2026ClinicalTrials.gov NCT06957691 · fetched Nov 12, 2026
- FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine TherapyPHASE2 · RECRUITING · started Dec 5, 2025ClinicalTrials.gov NCT06917313 · fetched Nov 12, 2026
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsPHASE1 · RECRUITING · started Jul 25, 2025ClinicalTrials.gov NCT07094204 · fetched Nov 12, 2026
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerPHASE2 · RECRUITING · started Apr 7, 2025ClinicalTrials.gov NCT06809140 · fetched Nov 12, 2026
- Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCCPHASE2 · RECRUITING · started Apr 1, 2025ClinicalTrials.gov NCT06553885 · fetched Nov 12, 2026
- Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerPHASE1_PHASE2 · RECRUITING · started Mar 31, 2025ClinicalTrials.gov NCT06470282 · fetched Nov 12, 2026
- A Study of Enfortumab Vedotin in People With Adenoid Cystic CarcinomaPHASE2 · RECRUITING · started Mar 31, 2025ClinicalTrials.gov NCT06891560 · fetched Nov 12, 2026
- Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder CancerPHASE1_PHASE2 · RECRUITING · started Sep 10, 2024ClinicalTrials.gov NCT06394570 · fetched Nov 12, 2026
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)PHASE1 · ACTIVE_NOT_RECRUITING · started Oct 25, 2023ClinicalTrials.gov NCT05756777 · fetched Nov 12, 2026
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyPHASE2 · RECRUITING · started Sep 26, 2023ClinicalTrials.gov NCT05756569 · fetched Nov 12, 2026
- A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary TractPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 2, 2023ClinicalTrials.gov NCT05868265 · fetched Nov 12, 2026
- A Study of ASP3082 in Adults With Advanced Solid TumorsPHASE1 · RECRUITING · started Jun 8, 2022ClinicalTrials.gov NCT05382559 · fetched Nov 12, 2026
- Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 2, 2022ClinicalTrials.gov NCT05239624 · fetched Nov 12, 2026
- ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerPHASE2 · RECRUITING · started Sep 8, 2021ClinicalTrials.gov NCT04986423 · fetched Nov 12, 2026
- Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCPHASE3 · ACTIVE_NOT_RECRUITING · started May 12, 2021ClinicalTrials.gov NCT04821622 · fetched Nov 12, 2026
- Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)PHASE3 · ACTIVE_NOT_RECRUITING · started Apr 21, 2021ClinicalTrials.gov NCT04700124 · fetched Nov 12, 2026
- Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 18, 2017ClinicalTrials.gov NCT03395197 · fetched Nov 12, 2026
- A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 23, 2017ClinicalTrials.gov NCT03246347 · fetched Nov 12, 2026
- Enzalutamide for Patients With Androgen Receptor Positive Salivary CancersPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 14, 2016ClinicalTrials.gov NCT02749903 · fetched Nov 12, 2026
- Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast CancerPHASE2 · ACTIVE_NOT_RECRUITING · started May 19, 2016ClinicalTrials.gov NCT02750358 · fetched Nov 12, 2026
- Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 17, 2014ClinicalTrials.gov NCT02319837 · fetched Nov 12, 2026